More recently, A2AR antagonists were shown to be involved in the control of α-synuclein aggregation and prevention of the associated neurotoxicity, which suggests that A2AR antagonists may act as potential drugs for PD treatment [118]. The gene discussed is ADORA2A; the disease is Parkinson disease.